Innovus Pharmaceuticals Establishes over 36,000 Retail Stores as Vendors of Record for its FlutiCare™ Product in the US

San Diego, CA, June 2, 2015 (Newswire.com) - – Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company) www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter (“OTC”) and consumer products for men’s and women’s health, vitality and respiratory diseases announced today  that it has established over 36,000 retail stores as Vendors of Record for its acquired  FlutiCare™ OTC product for Allergic Rhinitis ahead of its potential Abbreviated New Drug Application (“ANDA”) approval by the Food and Drug Administration (“FDA”). The established Vendors of Record include:

·         Walmart®,

·         Walgreens®,

·         CVS®,

·         Rite Aid®,

·         Target®,

·         Kroger®,

·         Safeway®,

·         Ahold®,

·         Giant Eagle®,

·         Delhaize®,

·         Winn-Dixie® and

·         H.E.B®

“The ability of the Company to establish so many retail stores and extensive distribution channels in the U.S. before the potential approval of the product by the FDA, we believe, is a testimony to the medical need and to the large market opportunity for allergic rhinitis products estimated to be over $1billion,” said Dr. Bassam Damaj, President & CEO of the Innovus Pharma.

The Company currently projects a tentative potential approval of the ANDA for the OTC form of the drug in Q1 2016 and an anticipated launch in Q2 2016 pending approval by the FDA.

About FlutiCare™

Fluticasone propionate 50 mcg spray, is the No. 1 prescribed allergy treatment ingredient1 treatment for temporary relief of the symptoms of hay fever or upper respiratory allergies.2

Roughly 50 million people in the United States suffer from nasal allergies3, and allergies take a toll on sufferers:

• Nasal allergies can lead to fatigue, sleep disturbances, learning and attention problems and impaired function at work and/or school.4
• In 2010, Americans with allergic rhinitis (AR) spent approximately $17.5 billion on health- related costs, lost more than 6 million work and school days and made more than 16 million visits to the doctor.5
• 70 percent of sufferers treat their symptoms with prescription or OTC treatments6; however, 50 percent of them report they are not completely satisfied with their current method of treatment.7

References

[1] Sur D, et al. Treatment of Allergic Rhinitis. American Family Physician. Volume 81, Number 12, June 15, 2010.

[2] American College of Allergy, Asthma and Immunology: Allergy facts. Available at http://www.acaai.org/allergist/news/Pages/Allergy_Facts.aspx. Accessed July 2014.

[3] American College of Allergy, Asthma and Immunology: Allergic diseases and cognitive impairment. Available at http://www.acaai.org/allergist/allergies/Types/rhinitis/Pages/allergic-diseases-cognitive-impairment.aspx. Accessed July 2014.

[4] Academy of Allergy and Asthma in Primary Care: National impact of allergies. Available at http://www.aaapc.us/wp-content/uploads/2013/01/National-Impact-of-Allergies.pdf. Accessed July 2014.

[5] Scadding G, Punekar Y. EAACI 2006, Abstract 742.

[6] New Survey Reveals Many Patients Want More from Their Allergy Medication. Asthma and Allergy Foundation of America. Available at: http://www.aafa.org/display.cfm?id=7&sub=92&cont=529. Accessed April 24, 2014[7] Data on hand

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare™ OTC for Allergic Rhinitis.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myadroferti.com

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval of the ANDA in the U.S. or to be compliant with the requirements of any relevant regulatory authority relating to Fluticare™, to successfully commercialize this product and other products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein.  Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC.  Copies of these reports are available from the SEC's website or without charge from the Company.

# # #

Contact:

Kevin Holmes

Chesapeake Group

[email protected]

 ###